New Treatment Options for Attention-Deficit/Hyperactivity Disorder (ADHD): Part I. Transdermal Methylphenidate and Lisdexamfetamine

Marcia L. Buck, PharmD, FCCP; Kristi N. Hofer, PharmD; Michelle W. McCarthy, PharmD


Pediatr Pharm. 2008;14(3) 

In This Article


The treatment options for attentiondeficit/hyperactivity disorder (ADHD) continue to expand. In the past 3 years, the Food and Drug Administration (FDA) has approved several new products. This issue of Pediatric Pharmacotherapy will provide a review of two new treatment options for children with ADHD: a transdermal methylphenidate delivery system, and lisdexamfetamine, an inactive dexamphetamine pro-drug.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.